指南与共识心律失常

种族与民族同房颤患者口服抗凝及结局的关联:GWTG-AFIB注册研究

Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry.
指南 / 共识 · JAMA Cardiol · 2022-01-01

黑人患者较白人患者出院时接受任何抗凝药和直接口服抗凝药(DOAC)的调整比值比分别为0.75和0.73,且1年出血、卒中及死亡风险更高;西班牙裔患者卒中风险更高。

要点

  • 黑人房颤患者出院时接受OAC和DOAC的调整比值比分别为0.75和0.73,低于白人患者。
  • 黑人患者1年出血、卒中及死亡风险均高于白人患者。
  • 西班牙裔患者1年卒中风险高于白人患者。

核心结论

  • 黑人房颤患者较白人患者出院时接受抗凝治疗及DOAC的可能性更低,且1年出血、卒中和死亡风险更高。
  • 西班牙裔患者较白人患者1年卒中风险更高。
  • 需要干预以实现指南导向房颤管理中的用药公平。

研究设计与样本

  • 回顾性队列分析,使用GWTG-AFIB注册研究数据,该注册为住院房颤患者全国质量改进项目。
  • 暴露为注册中自我报告的种族和民族;主要结局为出院时直接口服抗凝药(DOAC)或华法林处方。

主要发现

  • 黑人患者较白人患者出院时接受任何抗凝药的调整比值比为0.75(95%CI 0.68-0.84),接受DOAC的调整比值比为0.73(95%CI 0.65-0.82)。
  • 西班牙裔患者较白人患者卒中风险aHR为2.02(95%CI 1.38-2.95)。

临床怎么用

  • 临床应关注黑人及西班牙裔房颤患者出院时抗凝处方的不足,尤其黑人患者DOAC使用率更低。
  • 对黑人及西班牙裔房颤患者需加强卒中风险评估与抗凝管理,黑人患者还需关注出血和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oral anticoagulation (OAC) is underprescribed in underrepresented racial and ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC prescribing relates to inequities in AF outcomes. OBJECTIVE: To compare OAC use at discharge and AF-related outcomes by race and ethnicity in the Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) registry. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort analysis used data from the GWTG-AFIB registry, a national quality improvement initiative for hospitalized patients with AF. All registry patients hospitalized with AF from 2014 to 2020 were included in the study. Data were analyzed from November 2021 to July 2022. EXPOSURES: Self-reported race and ethnicity assessed in GWTG-AFIB registry. MAIN OUTCOMES AND MEASURES: The primary outcome was prescription of direct-acting OAC (DOAC) or warfarin at discharge. Secondary outcomes included cumulative 1-year incidence of ischemic stroke, major bleeding, and mortality postdischarge. Outcomes adjusted for patient demographic, clinical, and socioeconomic characteristics as well as hospital factors. RESULTS: Among 69 553 patients hospitalized with AF from 159 sites between 2014 and 2020, 863 (1.2%) were Asian, 5062 (7.3%) were Black, 4058 (5.8%) were Hispanic, and 59 570 (85.6%) were White. Overall, 34 113 (49.1%) were women; the median (IQR) age was 72 (63-80) years, and the median (IQR) CHA2DS2-VASc score (calculated as congestive heart failure, hypertension, age 75 years and older, diabetes, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) was 4 (2-5). At discharge, 56 385 patients (81.1%) were prescribed OAC therapy, including 41 760 (74.1%) receiving DOAC. OAC prescription at discharge was lowest in Hispanic patients (3010 [74.2%]), followed by Black patients (3935 [77.7%]) Asian patients (691 [80.1%]), and White patients (48 749 [81.8%]). Black patients were less likely than White patients to be discharged while taking any anticoagulant (adjusted odds ratio, 0.75; 95% CI, 0.68-0.84) and DOACs (adjusted odds ratio, 0.73; 95% CI, 0.65-0.82). In 16 307 individuals with 1-year follow up data, bleeding risks (adjusted hazard ratio [aHR], 2.08; 95% CI, 1.53-2.83), stroke risks (aHR, 2.07; 95% CI, 1.34-3.20), and mortality risks (aHR, 1.22; 95% CI, 1.02-1.47) were higher in Black patients than White patients. Hispanic patients had higher stroke risk (aHR, 2.02; 95% CI, 1.38-2.95) than White patients. CONCLUSIONS AND RELEVANCE: In a national registry of hospitalized patients with AF, compared with White patients, Black patients were less likely to be discharged while taking anticoagulant therapy and DOACs in particular. Black and Hispanic patients had higher risk of stroke compared with White patients; Black patients had a higher risk of bleeding and mortality. There is an urgent need for interventions to achieve pharmacoequity in guideline-directed AF management to improve overall outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Essien, Chiswell, Kaltenbach, et al. Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry. JAMA Cardiol. 2022. PMID: 36287545. doi:10.1001/jamacardio.2022.3704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。